Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-332-3410
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.93 million
Profitability
Miscellaneous
Employees63
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable
Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
How were Mirati Therapeutics' earnings last quarter?
Mirati Therapeutics Inc (NASDAQ:MRTX) issued its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.85) EPS for the quarter, topping the Zacks' consensus estimate of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History.
When is Mirati Therapeutics' next earnings date?
What price target have analysts set for MRTX?
13 brokers have issued 12-month price objectives for Mirati Therapeutics' shares. Their predictions range from $37.00 to $85.00. On average, they anticipate Mirati Therapeutics' stock price to reach $68.80 in the next year. This suggests a possible upside of 8.7% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.
What is the consensus analysts' recommendation for Mirati Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.
What are Wall Street analysts saying about Mirati Therapeutics stock?
Here are some recent quotes from research analysts about Mirati Therapeutics stock:
- 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (3/7/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Neutral rating and 12-month price target of $66/share. Mirati shares are +300% since +70% YTD. We believe that current Street estimates reflect high expectations around the novel KRASi asset, and do not fully appreciate potential clinical, regulatory and commercial risks associated with the lead asset sitravatinib. KRASi asset will remain the near-term focus where first clinical data from Amgen (Neutral, covered by A. Young) (by mid-19) and Mirati (in 2H19) will each garner huge investor interest." (3/4/2019)
- 3. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018)
Has Mirati Therapeutics been receiving favorable news coverage?
News coverage about MRTX stock has been trending positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a coverage optimism score of 2.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Loxo Oncology (LOXO), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR) and Alkermes (ALKS).
What other stocks do shareholders of Mirati Therapeutics own?
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
- Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
- Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
- Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
- Temre Johnson, Director of Investor Relations & Corp. Communications
Who are Mirati Therapeutics' major shareholders?
Mirati Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.36%), Virtu Financial LLC (0.01%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.
Which major investors are buying Mirati Therapeutics stock?
MRTX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Virtu Financial LLC and Meeder Asset Management Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.
How do I buy shares of Mirati Therapeutics?
Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of MRTX stock can currently be purchased for approximately $63.27.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $2.23 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.
What is Mirati Therapeutics' official website?
How can I contact Mirati Therapeutics?
Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]
MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
